January 24, 2014

Promoting Active Surveillance Pharmacovigilance in China

At the 5th DIA China Annual Meeting “Patient Safety – A Sustained Focus from Scientific Ideas to Innovative Medicines” in Beijing, Global Medicines Program Director Andy Stergachis .  talked about the need for active surveillance pharmacovigilance. The DIA China meeting held May 13-15, 2013, attracted over 1,200 participants.  Stergachis highlighted five reasons for conducting active surveillance pharmacovigilance, namely:  (a) follow-up on safety signals; (2) investigate newer products that have a limited real-world safety profile; (3) calculate rates of and risk factors for adverse events; (4) complement other pharmacovigilance methods; and (5) monitor pregnancy outcomes following prenatal drug exposure.  View presentation.